Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many

Just a few weeks after Rhythm Pharmaceuticals $RYTM snagged an FDA OK for setmelanotide in 3 rare genetic disorders that trigger obesity, the biotech is struggling to make a good case for a crucial market expansion.